Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome
Files
Publication date
2022-08-15
Authors
Streng, Bianca M.M.
Bont, Marin
Delemarre, Eveline M.
Binnendijk, Rob S.
Smit, Gaby
den Hartog, Gerco
Coppus, Antonia M.W.
de Vries, Esther
Weijerman, Michel E.
Lamberts, Regina
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.
Keywords
COVID-19 vaccination, Down syndrome, SARS-CoV-2, antibody response, General Medicine
Citation
Streng, B M M, Bont, M, Delemarre, E M, Binnendijk, R S, Smit, G, den Hartog, G, Coppus, A M W, de Vries, E, Weijerman, M E, Lamberts, R, de Graaf, G, van der Klis, F R, Vidarsson, G, Rave, N, Bont, L J & Wildenbeest, J G 2022, 'Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome', The Journal of infectious diseases, vol. 226, no. 4, pp. 673-677. https://doi.org/10.1093/infdis/jiac235